Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/15/2021 06/16/2021 06/17/2021 06/18/2021 06/21/2021 Date
8343(c) 8404(c) 8383(c) 8384(c) 8405.5799 Last
1 254 639 1 563 171 1 617 289 3 563 894 287 539 Volume
-0.06% +0.73% -0.25% +0.01% +0.26% Change
More quotes
Financials (USD)
Sales 2021 30 966 M - -
Net income 2021 4 588 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 36,5x
Yield 2021 2,47%
Sales 2022 35 684 M - -
Net income 2022 6 881 M - -
Net Debt 2022 8 377 M - -
P/E ratio 2022 24,5x
Yield 2022 2,55%
Capitalization 152 B 152 B -
EV / Sales 2021 5,25x
EV / Sales 2022 4,49x
Nbr of Employees 76 100
Free-Float 95,7%
More Financials
Company
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with... 
Read more
Sector
Pharmaceuticals
Calendar
06/23Presentation
More about the company
Ratings of AstraZeneca PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ASTRAZENECA PLC
04:35aASTRAZENECA  : welcomes Court ruling on supply of its COVID-19 vaccine to Europe
AQ
04:04aASTRAZENECA  : India begins inoculating all adults with free shots
RE
04:04aASTRAZENECA  : India begins inoculating all adults with free shots
RE
02:53aTHE LATEST : Policy switch aims to boost India's vaccinations
AQ
12:21aSK BIOSCIENCE  : S.Korea's SK bioscience to invest $132 million to boost vaccine..
RE
06/20NEWS HIGHLIGHTS : Top Company News of the Day
DJ
06/20Philippines seals biggest COVID-19 vaccine order yet, for 40 mln Pfizer doses
RE
06/20Philippines seals deal for 40 mln Pfizer/BioNTech COVID-19 doses
RE
06/19ASTRAZENECA  : pringsteen on Broadway' clears way for AstraZeneca recipients to ..
AQ
06/18ASTRAZENECA  : Argentine lab makes first half million doses of Russian COVID-19 ..
RE
06/18Ontarians cancelling AZ doses after new guidance, province still offering dos..
AQ
06/18Health Care Down Amid Defensive Bias -- Health Care Roundup
DJ
06/18U.S.-CANADA BORDER COULD REOPEN TO F : Legault
AQ
06/18Eurostoxx 50 : European shares deepen losses after hawkish Fed comments
RE
06/18THE LATEST : Brazil to hit 500K deaths, 2nd highest globally
AQ
More news
News in other languages on ASTRAZENECA PLC
03:37aCOVID  : Sileri; su mix vaccini errore di comunicazione (Stampa)
06/20Inselbewohner in Brasilien für Studie gegen Covid-19 geimpft
06/19CORONAVIRUS : le point sur la pandémie dans le monde
06/19France-Castex doublement vacciné avec AstraZeneca
06/18Acciones europeas profundizan sus pérdidas tras los comentarios de la Fed
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Analysis
AstraZeneca : JPMorgan, Goldman Sachs delay workers' return to U.K. offices
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 133,03 $
Last Close Price 115,73 $
Spread / Highest target 47,7%
Spread / Average Target 14,9%
Spread / Lowest Target -16,8%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.47%151 865
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795